Alembic Pharmaceuticals Q2 Results Live : Alembic Pharmaceuticals declared their Q2 results on 07 Nov, 2024, reporting a topline increase of 3.33% and a profit rise of 12.33% year-over-year. Compared to the previous quarter, the company experienced a revenue growth of 5.52% and a profit increase of 14.16%.
The financial report also highlighted that selling, general, and administrative expenses rose by 3.08% quarter-over-quarter and increased by 12.82% year-over-year. This rise in expenses has raised concerns about the company’s cost management strategies.
Operating income saw a significant jump, up by 8.24% quarter-over-quarter and an impressive 29.09% year-over-year, indicating strong operational efficiency despite rising expenses. The earnings per share (EPS) for Q2 stood at ₹7.24, reflecting a 4.1% increase from the same period last year.
In terms of stock performance, Alembic Pharmaceuticals has faced a -4.34% return in the last week, although it boasts a 7.84% return over the past six months and a remarkable 42.2% year-to-date return.
As of now, Alembic Pharmaceuticals has a market capitalization of ₹21,226.85 Cr, with its stock trading between a 52-week high of ₹1303.9 and a low of ₹710.25. Analysts remain cautiously optimistic, with 1 analyst rating it a ‘Sell’, 6 ‘Hold’, and 2 giving a ‘Strong Buy’ rating.
The consensus recommendation, as of 08 Nov, 2024, is to ‘Hold’, reflecting a balanced view on the company’s performance and market conditions.
Alembic Pharmaceuticals Financials
| Period | Q2 | Q1 | Q-o-Q Growth | Q2 | Y-o-Y Growth |
|---|---|---|---|---|---|
| Total Revenue | 1647.98 | 1561.73 | +5.52% | 1594.93 | +3.33% |
| Selling/ General/ Admin Expenses Total | 391.47 | 379.77 | +3.08% | 346.99 | +12.82% |
| Depreciation/ Amortization | 70.51 | 69.04 | +2.13% | 67.56 | +4.37% |
| Total Operating Expense | 1466.36 | 1393.94 | +5.2% | 1454.24 | +0.83% |
| Operating Income | 181.62 | 167.79 | +8.24% | 140.69 | +29.09% |
| Net Income Before Taxes | 180.42 | 157.03 | +14.9% | 135.15 | +33.5% |
| Net Income | 153.4 | 134.37 | +14.16% | 136.56 | +12.33% |
| Diluted Normalized EPS | 7.24 | 6.84 | +5.78% | 6.95 | +4.1% |
